[ad_1]
By Davit Kirakosyan
10x Genomics, Inc. (NASDAQ:) shares dropped more than 12% after-hours following the company’s preliminary Q2 results, with revenue expected to be approximately $114.5 million (down 1% year-over-year), missing the Street estimate of $127.7 million.
“Our second quarter results fell short of our expectations,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “We continue to have strong confidence in our longer-term opportunity, technology leadership and the underlying strength of our markets. We are more excited than ever to deliver on the full potential of single cell and spatial biology.”
In 2017, altcoins were seen as experimental side projects to Bitcoin. By 2021, they became…
Shopping centers in Las Vegas have a unique opportunity to stand out by offering not…
Levitra, a widely recognized medication for treating erectile dysfunction (ED), has proven to be a…
Have you ever looked down at your carpet and wondered if there’s a budget-friendly way…
Counter-Strike 2 (CS2) has elevated the thrill of case openings, captivating both seasoned CS:GO veterans…
Trying to sell a car online should be simple, but sometimes buyers lose interest fast.…
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="600px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
